Our STN: BL 125020/3309

SUPPLEMENT APPROVAL
July 22, 2026

MedImmune, LLC
Attention: Vanita Dimri
One MedImmune Way
Gaithersburg, MD 20878

Dear Ms. Dimri:

We have approved your request received April 30, 2026, to supplement your Biologics License Application (BLA) submitted under section 351(a) of the Public Health Service Act for Influenza Vaccine Live, Intranasal (FluMist), manufactured at your MedImmune UK, Ltd (Speke, UK) and (b) (4) facilities, to include the 2026-2027 United States formulation and the associated labeling revisions.

LABELING

Under 21 CFR 201.57(c)(18), patient labeling must be referenced in section 17 PATIENT COUNSELING INFORMATION. Patient labeling must be available and may either be reprinted immediately following the full prescribing information of the package insert or accompany the prescription product labeling.

We hereby approve the draft content of labeling: Package Insert, Patient Package Insert, and Instructions for Use submitted under amendment 8, dated July 20, 2026, and the draft carton and container labels submitted on April 30, 2026.

We acknowledge your commitment to implement the labeling changes approved under this supplement for FluMist, at the next printing. We recognize that immediate reprinting of labels to incorporate the FDA-requested revisions would significantly impact the timely availability of vaccine supply for the 2026–2027 season. We also acknowledge your commitment to submit the final labels incorporating FDA-approved revisions under STN 125020/3309 in Structured Product Labeling (SPL) format no later than 14 days from the date of this letter.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, please submit the final content of labeling (21 CFR 601.14) in Structured Product Labeling (SPL) format via the FDA automated drug registration and listing system, (eLIST) as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the Package Insert, Patient Package Insert, and Instructions for Use submitted on July 20, 2026. Information on

submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As* at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf.

The SPL will be accessible via publicly available labeling repositories.

CARTON AND CONTAINER LABELS

Please electronically submit final printed carton and container labels identical to the carton and container labels submitted on April 30, 2026, according to the guidance for industry *Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications* at https://www.fda.gov/regulatory-information/search-fda-guidance-documents/providing-regulatory-submissions-electronic-format-certain-human-pharmaceutical-product-applications.

All final labeling should be submitted as Product Correspondence to this BLA, STN BL 125020 at the time of use and include implementation information on Form FDA 356h.

ADVERTISING AND PROMOTIONAL LABELING

You may submit two draft copies of the proposed introductory advertising and promotional labeling with Form FDA 2253 to the Advertising and Promotional Labeling Branch at the following address:

Food and Drug Administration
Center for Biologics Evaluation and Research
Document Control Center
10903 New Hampshire Ave.
WO71–G112
Silver Spring, MD 20993-0002

You must submit copies of your final advertising and promotional labeling at the time of initial dissemination or publication, accompanied by Form FDA 2253 (21 CFR 601.12(f)(4)).

All promotional claims must be consistent with and not contrary to approved labeling. You should not make a comparative promotional claim or claim of superiority over other products unless you have substantial evidence or substantial clinical experience to support such claims (21 CFR 202.1(e)(6)).

For each pending supplemental application for this BLA that includes proposed revised labeling, please submit an amendment to update the proposed revised labeling with the changes approved today.

We will include the information contained in the above-referenced supplement in your BLA file.

Sincerely,

Jerry P. Weir, PhD
Director
Division of Viral Products
Office of Vaccines Research and Review
Center for Biologics Evaluation and Research